182 related articles for article (PubMed ID: 29189139)
1. Lipid nanoparticles for the delivery of active natural medicines.
Xing H; Wang H; Wu B; Zhang X
Curr Pharm Des; 2017 Nov; ():. PubMed ID: 29189139
[TBL] [Abstract][Full Text] [Related]
2. Natural Lipids as Structural Components of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Topical Delivery.
Dobreva M; Stefanov S; Andonova V
Curr Pharm Des; 2020; 26(36):4524-4535. PubMed ID: 32410552
[TBL] [Abstract][Full Text] [Related]
3. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticles and Active Natural Compounds: A Perfect Combination for Pharmaceutical Applications.
Puglia C; Pignatello R; Fuochi V; Furneri PM; Lauro MR; Santonocito D; Cortesi R; Esposito E
Curr Med Chem; 2019; 26(24):4681-4696. PubMed ID: 31203795
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured Lipid Carriers- A Versatile Carrier for Oral Delivery of Lipophilic Drugs.
Patel P; Patel M
Recent Pat Nanotechnol; 2021; 15(2):154-164. PubMed ID: 32912129
[TBL] [Abstract][Full Text] [Related]
6. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers.
Shidhaye SS; Vaidya R; Sutar S; Patwardhan A; Kadam VJ
Curr Drug Deliv; 2008 Oct; 5(4):324-31. PubMed ID: 18855604
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
Banerjee S; Pillai J
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
[No Abstract] [Full Text] [Related]
8. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
9. Current applications of solid lipid nanoparticles and nanostructured lipid carriers as vehicles in oral delivery systems for antioxidant nutraceuticals: A review.
Gunawan M; Boonkanokwong V
Colloids Surf B Biointerfaces; 2024 Jan; 233():113608. PubMed ID: 37925866
[TBL] [Abstract][Full Text] [Related]
10. Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review.
Viegas C; Patrício AB; Prata JM; Nadhman A; Chintamaneni PK; Fonte P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376042
[TBL] [Abstract][Full Text] [Related]
11. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review.
Garcês A; Amaral MH; Sousa Lobo JM; Silva AC
Eur J Pharm Sci; 2018 Jan; 112():159-167. PubMed ID: 29183800
[TBL] [Abstract][Full Text] [Related]
12. Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases.
Cunha S; Almeida H; Amaral MH; Lobo JMS; Silva AC
Curr Pharm Des; 2017 Nov; ():. PubMed ID: 29189138
[TBL] [Abstract][Full Text] [Related]
13. Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
Okur NÜ; Siafaka PI; Gökçe EH
Curr Pharm Biotechnol; 2021; 22(7):892-905. PubMed ID: 32753006
[TBL] [Abstract][Full Text] [Related]
14. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery.
Teixeira MC; Carbone C; Souto EB
Prog Lipid Res; 2017 Oct; 68():1-11. PubMed ID: 28778472
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers (NLC) in cosmetic dermal products.
Müller RH; Petersen RD; Hommoss A; Pardeike J
Adv Drug Deliv Rev; 2007 Jul; 59(6):522-30. PubMed ID: 17602783
[TBL] [Abstract][Full Text] [Related]
16. SLN and NLC for topical, dermal, and transdermal drug delivery.
Souto EB; Baldim I; Oliveira WP; Rao R; Yadav N; Gama FM; Mahant S
Expert Opin Drug Deliv; 2020 Mar; 17(3):357-377. PubMed ID: 32064958
[No Abstract] [Full Text] [Related]
17. Solid Lipid Nanoparticles: A Potential Option for Enhancing Oral Bioavailability of Highly Soluble and Poorly Permeable (BCS Class III) Drugs.
Sri Rekha M ; Sangeetha S ; Seetha Devi A
Curr Drug Deliv; 2023; 20(3):223-236. PubMed ID: 35443896
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of drug delivery by means of lipid nanoparticles: reality or illusion?
Uner M; Damgalı S; Ozdemir S; Celik B
Curr Pharm Des; 2017 Nov; ():. PubMed ID: 29173153
[TBL] [Abstract][Full Text] [Related]
19. Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration.
Fonseca-Santos B; Silva PB; Rigon RB; Sato MR; Chorilli M
Curr Med Chem; 2020; 27(22):3623-3656. PubMed ID: 31232233
[TBL] [Abstract][Full Text] [Related]
20. Solid lipid nanocarriers in drug delivery: characterization and design.
Mu H; Holm R
Expert Opin Drug Deliv; 2018 Aug; 15(8):771-785. PubMed ID: 30064267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
